Markers of polyfunctional sars-cov-2 antibodies in convalescent plasma

Harini Natarajan, Andrew R. Crowley, Savannah E. Butler, Shiwei Xu, Joshua A. Weiner, Evan M. Bloch, Kirsten Littlefield, Wendy Wieland-Alter, Ruth I. Connor, Peter F. Wright, Sarah E. Benner, Tania S. Bonny, Oliver Laeyendecker, David Sullivan, Shmuel Shoham, Thomas C. Quinn, H. Benjamin Larman, Arturo Casadevall, Andrew Pekosz, Andrew D. ReddAaron A.R. Tobian, Margaret E. Ackerman

Research output: Contribution to journalArticlepeer-review

Abstract

Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as well as an additional 20 convalescent individuals as a validation cohort. Multiplexed Fc Array binding assays and functional antibody response assays were utilized to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody composition and activ-ity. Donor convalescent plasma samples contained a range of antibody cell-and complement-mediated effector functions, indicating the diverse antiviral activity of humoral responses observed among recovered individuals. In addition to viral neutralization, convalescent plasma samples contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis, and antibody-dependent cellular cytotoxicity against SARS-CoV-2. Plasma samples from a fraction of eligible donors exhibited high activity across all activities eval-uated. These polyfunctional plasma samples could be identified with high accu-racy with even single Fc Array features, whose correlation with polyfunctional activity was confirmed in the validation cohort. Collectively, these results expand understanding of the diversity of antibody-mediated antiviral functions associated with convalescent plasma, and the polyfunctional antiviral functions suggest that it could retain activity even when its neutralizing capacity is reduced by mutations in variant SARS-CoV-2. IMPORTANCE Convalescent plasma has been deployed globally as a treatment for COVID-19, but efficacy has been mixed. Better understanding of the antibody characteristics that may contribute to its antiviral effects is important for this intervention as well as offer insights into correlates of vaccine-mediated protection. Here, a sur-vey of convalescent plasma activities, including antibody neutralization and diverse effector functions, was used to define plasma samples with broad activity profiles. These polyfunctional plasma samples could be reliably identified in multiple cohorts by multiplex assay, presenting a widely deployable screening test for plasma selection and investigation of vaccine-elicited responses.

Original languageEnglish (US)
Article numbere00765-21
JournalmBio
Volume12
Issue number2
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Microbiology
  • Virology

Fingerprint

Dive into the research topics of 'Markers of polyfunctional sars-cov-2 antibodies in convalescent plasma'. Together they form a unique fingerprint.

Cite this